Perispinal etanercept: a new therapeutic paradigm in neurology

References

• Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev.18(3–4), 335–343 (2007).
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.117(2), 244–279 (2008).
   PubMed Web of Science ®Google Scholar
• Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol.19(4), 223–230 (1999).
   PubMed Web of Science ®Google Scholar
• Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry74(9), 1200–1205 (2003).
   PubMed Web of Science ®Google Scholar
• Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs23(9), 713–725 (2009).
   PubMed Web of Science ®Google Scholar
• Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Soluble TNF receptors are associated with Ab metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging.2008.10.012 (2008) (Epub ahead of print).
   Google Scholar
• Ferguson AR, Christensen RN, Gensel JC et al. Cell death after spinal cord injury is exacerbated by rapid TNF α-induced trafficking of GluR2-lacking AMPARs to the plasma membrane. J. Neurosci.28(44), 11391–11400 (2008).
   PubMed Web of Science ®Google Scholar
• McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation5, 45 (2008).
   PubMed Web of Science ®Google Scholar
• Sjogren M, Folkesson S, Blennow K, Tarkowski E. Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J. Neurol. Neurosurg. Psychiatry75(8), 1107–1111 (2004).
   PubMed Web of Science ®Google Scholar
• Tweedie D, Sambamurti K, Greig NH. TNF-α inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res.4(4), 378–385 (2007).
   PubMed Web of Science ®Google Scholar
• Uceyler N, Sommer C. Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci. Lett.437(3), 194–198 (2008).
   PubMed Web of Science ®Google Scholar
• Van Eldik LJ, Thompson WL, Ranaivo HR, Behanna HA, Watterson DM. Proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int. Rev. Neurobiol.82, 278–297 (2007).
   Google Scholar
• Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol. Med.13(2), 54–63 (2007).
   PubMed Web of Science ®Google Scholar
• Bains JS, Oliet SH. Glia: they make your memories stick! Trends Neurosci.30(8), 417–424 (2007).
   PubMed Web of Science ®Google Scholar
• Oliet SH, Piet R, Poulain DA, Theodosis DT. Glial modulation of synaptic transmission: insights from the supraoptic nucleus of the hypothalamus. Glia47(3), 258–267 (2004).
   Google Scholar
• De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F. Chronic expression of low levels of tumor necrosis factor-α in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol. Dis.37(3), 630–640 (2010).
   PubMedGoogle Scholar
• Floden AM, Li S, Combs CK. β-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor a and NMDA receptors. J. Neurosci.25(10), 2566–2575 (2005).
   PubMed Web of Science ®Google Scholar
• Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J.23(8), 2502–2513 (2009).
   PubMed Web of Science ®Google Scholar
• Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-α and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer’s disease mice. J. Neuroinflammation2, 23 (2005).
   PubMedGoogle Scholar
• Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging26(3), 349–354 (2005).
   PubMed Web of Science ®Google Scholar
• Ranaivo HR, Craft JM, Hu W et al. Glia as a therapeutic target: selective suppression of human amyloid-β-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J. Neurosci.26(2), 662–670 (2006).
   Google Scholar
• Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA, Martin Watterson D. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int. Rev. Neurobiol.82, 277–296 (2007).
   PubMed Web of Science ®Google Scholar
• Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov. Today14(3–4), 168–177 (2009).
   PubMed Web of Science ®Google Scholar
• Tobinick EL, Britschgi-Davoodifar S. Perispinal TNF-α inhibition for discogenic pain. Swiss Med. Wkly133(11–12), 170–177 (2003).
   PubMed Web of Science ®Google Scholar
• Sommer C, Schafers M. Mechanisms of neuropathic pain: the role of cytokines. Drug Discov. Today1(4), 441–448 (2004).
   Google Scholar
• Myers RR, Campana WM, Shubayev VI. The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov. Today11(1–2), 8–20 (2006).
   PubMed Web of Science ®Google Scholar
• Homma Y, Brull SJ, Zhang JM. A comparison of chronic pain behavior following local application of tumor necrosis factor a to the normal and mechanically compressed lumbar ganglia in the rat. Pain95(3), 239–246 (2002).
   PubMed Web of Science ®Google Scholar
• Onda A, Hamba M, Yabuki S, Kikuchi S. Exogenous tumor necrosis factor-α induces abnormal discharges in rat dorsal horn neurons. Spine27(15), 1618–1624; discussion 1624 (2002).
   PubMedGoogle Scholar
• Aoki Y, Rydevik B, Kikuchi S, Olmarker K. Local application of disc-related cytokines on spinal nerve roots. Spine (Phila Pa 1976)27(15), 1614–1617 (2002).
   Google Scholar
• Sorkin LS, Doom CM. Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J. Peripher. Nerv. Syst.5(2), 96–100 (2000).
   PubMed Web of Science ®Google Scholar
• Igarashi T, Kikuchi S, Shubayev V, Myers RR. 2000 Volvo Award winner in basic science studies: exogenous tumor necrosis factor-α mimics nucleus pulposus-induced neuropathology. Molecular, histologic, and behavioral comparisons in rats. Spine (Phila Pa 1976)25(23), 2975–2980 (2000).
   PubMed Web of Science ®Google Scholar
• Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-α prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine (Phila Pa 1976)26(8), 863–869 (2001).
   PubMed Web of Science ®Google Scholar
• Murata Y, Olmarker K, Takahashi I, Takahashi K, Rydevik B. Effects of selective tumor necrosis factor-α inhibition to pain-behavioral changes caused by nucleus pulposus-induced damage to the spinal nerve in rats. Neurosci. Lett.382(1–2), 148–152 (2005).
   PubMedGoogle Scholar
• Olmarker K, Nutu M, Storkson R. Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-α inhibition. Spine28(15), 1635–1641; discussion 1642 (2003).
   PubMed Web of Science ®Google Scholar
• Sekiguchi M, Kikuchi S, Myers RR. Experimental spinal stenosis: relationship between degree of cauda equina compression, neuropathology, and pain. Spine (Phila Pa 1976)29(10), 1105–1111 (2004).
   PubMedGoogle Scholar
• Igarashi A, Kikuchi S, Konno S, Olmarker K. Inflammatory cytokines released from the facet joint tissue in degenerative lumbar spinal disorders. Spine29(19), 2091–2095 (2004).
   PubMed Web of Science ®Google Scholar
• Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J. Peripher. Nerv. Syst.6(2), 67–72 (2001).
   PubMed Web of Science ®Google Scholar
• Kato K, Kikuchi S, Shubayev VI, Myers RR. Distribution and tumor necrosis factor-α isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience160(2), 492–500 (2009).
   Google Scholar
• Kato K, Liu H, Kikuchi SI, Myers RR, Shubayev VI. Immediate anti-tumor necrosis factor-α (etanercept) therapy enhances axonal regeneration after sciatic nerve crush. J. Neurosci. Res.88(2), 360–368 (2009).
   Google Scholar
• Tobinick E, Vega CP. The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed8(1), 53 (2006).
   PubMedGoogle Scholar
• Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann. Surg.112, 138–149 (1940).
   PubMedGoogle Scholar
• Batson OV. The vertebral vein system. Caldwell lecture, 1956. Am. J. Roentgenol. Radium Ther. Nucl. Med.78(2), 195–212 (1957).
   PubMedGoogle Scholar
• Tobinick EL. Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clin. Ther.25(4), 1211–1218 (2003).
   PubMed Web of Science ®Google Scholar
• Tobinick E, Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr. Med. Res. Opin.20(7), 1075–1085 (2004).
   PubMed Web of Science ®Google Scholar
• Kume K, Amano K, Yamada S. The efficacy and safety of caudal epidural injection with the TNF-α antagonist, etanercept, in patients with disc-herniation-induced sciatica: results of a randomized, controlled, 1-month follow-up study. Ann. Rheum. Dis.67(Suppl. II), 131 (2008).
   PubMedGoogle Scholar
• Shin K, Lee S, Moon S et al. A prospective controlled trial of TNF-α inhibitor for symptomatic patients with cervical disk herniation. Spine J.5(4), S45 (2005).
   Google Scholar
• Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann. Rheum. Dis.63(9), 1120–1123 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen SP, Bogduk N, Dragovich A et al. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology110(5), 1116–1126 (2009).
   PubMed Web of Science ®Google Scholar
• Kume K, Amano A, Yamada S, Nagata H. The efficacy and safety of caudal epidural injection with the TNF-αntagonist, adalimumab and etanercept, in patients with disc-herniation-induced sciatica. Results of a randomized, controlled, 1-month follow-up study. Presented at: 2009 Annual Meeting of the American College of Rheumatology. Philadelphia, PA, USA, 17–21 October 2009.
   Google Scholar
• Furst DE, Keystone EC, Fleischmann R et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann. Rheum. Dis.69(Suppl. 1), i2–i29 (2010).
   PubMed Web of Science ®Google Scholar
• Payne R, Inturrisi CE. CSF distribution of morphine, methadone and sucrose after intrathecal injection. Life Sci.37(12), 1137–1144 (1985).
   PubMed Web of Science ®Google Scholar
• Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease therapeutics. BMC Med.7, 7 (2009).
   PubMed Web of Science ®Google Scholar
• Querfurth HW, LaFerla FM. Alzheimer’s Disease. N. Engl. J. Med.362(4), 329–344 (2010).
   PubMed Web of Science ®Google Scholar
• Alkam T, Nitta A, Mizoguchi H et al. Restraining tumor necrosis factor-α by thalidomide prevents the amyloid β-induced impairment of recognition memory in mice. Behav. Brain Res.189(1), 100–106 (2008).
   PubMed Web of Science ®Google Scholar
• Giuliani F, Vernay A, Leuba G, Schenk F. Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-α metabolism. Brain Res. Bull.80(4–5), 302–308 (2009).
   Google Scholar
• Hu NW, Klyubin I, Anwy R, Rowan MJ. GluN2B subunit-containing NMDA receptor antagonists prevent Aβ-mediated synaptic plasticity disruption in vivo. Proc. Natl Acad. Sci. USA106(48), 20504–20509 (2009).
   PubMed Web of Science ®Google Scholar
• Medeiros R, Figueiredo CP, Pandolfo P et al. The role of TNF-α signaling pathway on COX-2 upregulation and cognitive decline induced by β-amyloid peptide. Behav. Brain Res.209(1), 165–173 (2010).
   PubMed Web of Science ®Google Scholar
• Medeiros R, Prediger RD, Passos GF et al. Connecting TNF-α signaling pathways to iNOS expression in a mouse model of Alzheimer’s disease: relevance for the behavioral and synaptic deficits induced by amyloid b protein. J. Neurosci.27(20), 5394–5404 (2007).
   Web of Science ®Google Scholar
• Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R. Synaptic memory mechanisms: Alzheimer’s disease amyloid β-peptide-induced dysfunction. Biochem. Soc. Trans.35(Pt 5), 1219–1223 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Q, Wu J, Rowan MJ, Anwyl R. β-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J. Neurosci.22(11), 2827–2832 (2005).
   PubMed Web of Science ®Google Scholar
• Tobinick E. Perispinal etanercept for treatment of Alzheimer’s disease. Curr. Alzheimer Res.4(5), 550–552 (2007).
   PubMed Web of Science ®Google Scholar
• Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J. Neuroinflammation5, 2 (2008).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kiyota T, Horiba M et al. Interferon-γ and tumor necrosis factor-α regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice. Am. J. Pathol.170(2), 680–692 (2007).
   PubMed Web of Science ®Google Scholar
• Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS. Tumor necrosis factor-α, interleukin-1β, and Interferon-γ stimulate γ-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem.279(47), 49523–49532 (2004).
   PubMed Web of Science ®Google Scholar
• Combs CK, Karlo JC, Kao SC, Landreth GE. β-amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci.21(4), 1179–1188 (2001).
   PubMed Web of Science ®Google Scholar
• Ishii W, Kishida D, Suzuki A et al. A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept. Rheumatol. Int. DOI: 10.007.600296-009-1205-2 (2009) (Epub ahead of print).
   Google Scholar
• Hussein MA, Juturi JV, Rybicki L, Lutton S, Murphy BR, Karam MA. Etanercept therapy in patients with advanced primary amyloidosis. Med. Oncol.20(3), 283–290 (2003).
   PubMedGoogle Scholar
• Salloway S, Sperling R, Gilman S et al. A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology73(24), 2061–2070 (2009).
   PubMed Web of Science ®Google Scholar
• Cacci E, Ajmone-Cat MA, Anelli T, Biagioni S, Minghetti L. In vitro neuronal and glial differentiation from embryonic or adult neural precursor cells are differently affected by chronic or acute activation of microglia. Glia56(4), 412–425 (2008).
   PubMed Web of Science ®Google Scholar
• Holmes C, Cunningham C, Zotova E et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology73(10), 768–774 (2009).
   PubMed Web of Science ®Google Scholar
• Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging21(3), 383–421 (2000).
   PubMed Web of Science ®Google Scholar
• Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer’s disease. Glia58(3), 300–314 (2010).
   PubMed Web of Science ®Google Scholar
• Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer’s disease. Neurobiol. Aging22(6), 873–883 (2001).
   PubMed Web of Science ®Google Scholar
• Alvarez V, Mata IF, Gonzalez P et al. Association between the TNFα-308 A/G polymorphism and the onset-age of Alzheimer disease. Am. J. Med. Genet.114(5), 574–577 (2002).
   Google Scholar
• Tan ZS, Beiser AS, Vasan RS et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology68(22), 1902–1908 (2007).
   PubMed Web of Science ®Google Scholar
• Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res. Bull.61(3), 255–260 (2003).
   PubMed Web of Science ®Google Scholar
• van Exel E, Eikelenboom P, Comijs H et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch. Gen. Psychiatry66(11), 1263–1270 (2009).
   PubMed Web of Science ®Google Scholar
• Park KM, Bowers WJ. Tumor necrosis factor-α mediated signaling in neuronal homeostasis and dysfunction. Cell. Signal.22(7), 977–983 (2010).
   PubMed Web of Science ®Google Scholar
• Di Bona D, Candore G, Franceschi C et al. Systematic review by meta-analyses on the possible role of TNF-α polymorphisms in association with Alzheimer’s disease. Brain Res. Rev.61(2), 60–68 (2009).
   PubMedGoogle Scholar
• Laws SM, Perneczky R, Wagenpfeil S et al. TNF polymorphisms in Alzheimer disease and functional implications on CSF β-amyloid levels. Hum. Mutat.26(1), 29–35 (2005).
   PubMed Web of Science ®Google Scholar
• Lio D, Annoni G, Licastro F et al. Tumor necrosis factor-α -308A/G polymorphism is associated with age at onset of Alzheimer’s disease. Mech. Ageing Dev.127(6), 567–571 (2006).
   PubMed Web of Science ®Google Scholar
• Ramos EM, Lin MT, Larson EB et al. Tumor necrosis factor a and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch. Neurol.63(8), 1165–1169 (2006).
   Google Scholar
• Zuliani G, Ranzini M, Guerra G et al. Plasma cytokines profile in older subjects with late onset Alzheimer’s disease or vascular dementia. J. Psychiatr. Res.41(8), 686–693 (2006).
   Google Scholar
• Tobinick E, Gross H, Weinberger A, Cohen H. TNF-α modulation for treatment of Alzheimer’s disease: a 6-month pilot study. MedGenMed8(2), 25 (2006).
   PubMedGoogle Scholar
• Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol.8, 27 (2008).
   PubMed Web of Science ®Google Scholar
• Tobinick E. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J. Med.10(6), 135 (2008).
   PubMedGoogle Scholar
• Groen RJ, du Toit DF, Phillips FM et al. Anatomical and pathological considerations in percutaneous vertebroplasty and kyphoplasty: a reappraisal of the vertebral venous system. Spine (Phila Pa 1976)29(13), 1465–1471 (2004).
   Google Scholar
• Vallejo MC, Beaman ST, Ramanathan S. Blurred vision as the only symptom of a positive epidural test dose. Anesth. Analg.102(3), 973–974 (2006).
   Google Scholar
• Anderson R. Diodrast studies of the vertebral and cranial venous systems to show their probable role in cerebral metastases. J. Neurosurg.8(4), 411–422 (1951).
   Google Scholar
• Hassler O. Deep cerebral venous system in man. A microangiographic study on its areas of drainage and its anastomoses with the superficial cerebral veins. Neurology16(5), 505–511 (1966).
   Google Scholar
• Wacnik PW, Eikmeier LJ, Simone DA, Wilcox GL, Beitz AJ. Nociceptive characteristics of tumor necrosis factor-α in naive and tumor-bearing mice. Neuroscience132(2), 479–491 (2005).
   PubMed Web of Science ®Google Scholar
• Lorberboym M, Lampl Y, Sadeh M. Correlation of 99mTc-DTPA SPECT of the blood–brain barrier with neurologic outcome after acute stroke. J. Nucl. Med.44(12), 1898–1904 (2003).
   PubMed Web of Science ®Google Scholar
• Bohac D, Burke W, Cotter R, Zheng J, Potter J, Gendelman H. A 24-week randomized, double-blind, placebo-controlled study of the efficacy and tolerability of TNFR: Fc (etanercept) in the treatment of dementia of the Alzheimer type. Neurobiol. Aging23(1 Suppl. 1), S1–S606 (2002) (Abstract 315).
   Google Scholar
• Cao Q, Cai W, Li ZB et al. PET imaging of acute and chronic inflammation in living mice. Eur. J. Nucl. Med. Mol. Imaging34(11), 1832–1842 (2007).
   Google Scholar
• Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res. Notes2, 28 (2009).
   PubMedGoogle Scholar
• Maness LM, Banks WA, Zadina JE, Kastin AJ. Selective transport of blood-borne interleukin-1 a into the posterior division of the septum of the mouse brain. Brain Res.700(1–2), 83–88 (1995).
   PubMed Web of Science ®Google Scholar
• Pfefferbaum A, Adalsteinsson E, Sullivan EV. In vivo structural imaging of the rat brain with a 3-T clinical human scanner. J. Magn. Reson. Imaging20(5), 779–785 (2004).
   Google Scholar
• Quan N, Mhlanga JD, Whiteside MB, McCoy AN, Kristensson K, Herkenham M. Chronic overexpression of proinflammatory cytokines and histopathology in the brains of rats infected with Trypanosoma brucei. J. Comp. Neurol.414(1), 114–130 (1999).
   PubMed Web of Science ®Google Scholar
• Yanamoto K, Zhang MR, Kumata K, Hatori A, Okada M, Suzuki K. In vitro and ex vivo autoradiography studies on peripheral-type benzodiazepine receptor binding using [11C]AC-5216 in normal and kainic acid-lesioned rats. Neurosci. Lett.428(2–3), 59–63 (2007).
   Google Scholar
• Johanson CE, Duncan JA, Stopa EG, Baird A. Enhanced prospects for drug delivery and brain targeting by the choroid plexus–CSF route. Pharm. Res.22(7), 1011–1037 (2005).
   Google Scholar
• Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J. Blood–brain barrier permeability in Alzheimer’s disease: a case–control MRI study. Psychiatry Res.171(3), 232–241 (2009).
   PubMed Web of Science ®Google Scholar
• Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood–brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer’s disease. Neurobiol. Dis.8(4), 555–567 (2001).
   Google Scholar
• Clark SR, McMahon CJ, Gueorguieva I et al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J. Cereb. Blood Flow Metab.28(2), 387–394 (2008).
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol.3(7), 569–581 (2003).
   PubMed Web of Science ®Google Scholar
• Johanson CE, Duncan JA 3rd, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res.5, 10 (2008).
   PubMedGoogle Scholar
• Serot JM, Bene MC, Faure GC. Choroid plexus, aging of the brain, and Alzheimer’s disease. Front. Biosci.8, S515–S521 (2003).
   Google Scholar
• Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J. Neuroinflammation5, 3 (2008).
   PubMed Web of Science ®Google Scholar
• Pelletier M, Siegel RM. Wishing away inflammation? New links between serotonin and TNF signaling. Mol. Interv.9(6), 299–301 (2009).
   Google Scholar
• Chavant F, Deguil J, Pain S et al. Imipramine, in part through tumor necrosis factor a inhibition, prevents cognitive decline and β-amyloid accumulation in a mouse model of Alzheimer’s disease. J. Pharmacol. Exp. Ther.332(2), 505–514 (2010).
   Google Scholar
• Wheeler D, Knapp E, Bandaru VV et al. Tumor necrosis factor-α-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J. Neurochem.109(5), 1237–1249 (2009).
   PubMed Web of Science ®Google Scholar
• Nygard M, Lundkvist GB, Hill RH, Kristensson K. Rapid nitric oxide-dependent effects of tumor necrosis factor-α on suprachiasmatic nuclei neuronal activity. Neuroreport20(2), 213–217 (2009).
   PubMed Web of Science ®Google Scholar
• Wang Y. P4-266: modification of synaptic plasticity by TNF and sphingomyelinase: implications for cognitive impairment in Alzheimer’s disease. Alzheimers Dement.4(4 Suppl.), T749 (2008).
   Google Scholar
• Wolinsky H. Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against ‘accepted wisdom’. EMBO Rep.9(5), 416–418 (2008).
   Google Scholar
• Youn DH, Wang H, Jeong SJ. Exogenous tumor necrosis factor-α rapidly alters synaptic and sensory transmission in the adult rat spinal cord dorsal horn. J. Neurosci. Res.86(13), 2867–2875 (2008).
   Google Scholar
• Maarouf CL, Daugs ID, Spina S et al. Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol. Neurodegener.3, 20 (2008).
   Google Scholar
• Passant U, Rosen I, Gustafson L, Englund E. The heterogeneity of frontotemporal dementia with regard to initial symptoms, qEEG and neuropathology. Int. J. Geriatr. Psychiatry20(10), 983–988 (2005).
   Google Scholar
• Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology35(4), 453–461 (1985).
   PubMed Web of Science ®Google Scholar
• Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology69(24), 2197–2204 (2007).
   PubMed Web of Science ®Google Scholar
• Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer’s disease and other forms of dementia: clinical needs, limitations and future aspects. Exp. Gerontol.45(1), 5–14 (2009).
   Google Scholar
• Fagan AM, Csernansky CA, Morris JC, Holtzman DM. The search for antecedent biomarkers of Alzheimer’s disease. J. Alzheimers Dis.8(4), 347–358 (2005).
   PubMed Web of Science ®Google Scholar
• Halperin I, Morelli M, Korczyn AD, Youdim MB, Mandel SA. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases. Neurotherapeutics6(1), 128–140 (2009).
   PubMed Web of Science ®Google Scholar
• Wilcock GK. Bapineuzumab in Alzheimer’s disease: where now? Lancet Neurol.9(2), 134–136 (2010).
   Google Scholar
• Beattie EC, Stellwagen D, Morishita W et al. Control of synaptic strength by glial TNFα. Science295(5563), 2282–2285 (2002).
   PubMed Web of Science ®Google Scholar
• Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-α. Nature440(7087), 1054–1059 (2006).
   PubMed Web of Science ®Google Scholar
• Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-α. J. Neurosci.25(12), 3219–3228 (2005).
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc.53(4), 695–699 (2005).
   PubMed Web of Science ®Google Scholar
• Vellas B. Tarenflurbil for Alzheimer’s disease: a “shot on goal” that missed. Lancet Neurol.9(3), 235–237 (2010).
   Google Scholar
• Harrison JE, Buxton P, Husain M, Wise R. Short test of semantic and phonological fluency: normal performance, validity and test–retest reliability. Br. J. Clin. Psychol.39(Pt 2), 181–191 (2000).
   PubMed Web of Science ®Google Scholar
• Fisher NJ, Tierney MC, Rourke BP, Szalai JP. Verbal fluency patterns in two subgroups of patients with Alzheimer’s disease. Clin. Neuropsychol.18(1), 122–131 (2004).
   PubMed Web of Science ®Google Scholar
• Simonsick EM, Gardner AW, Poehlman ET. Assessment of physical function and exercise tolerance in older adults: reproducibility and comparability of five measures. Aging (Milano)12(4), 274–280 (2000).
   Google Scholar
• Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised Phase III trial. Lancet367(9504), 29–35 (2006).
   PubMed Web of Science ®Google Scholar
• Apkarian AV, Sosa Y, Sonty S et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J. Neurosci.24(46), 10410–10415 (2004).
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry67(5), 446–457 (2009).
   Google Scholar
• Amgen Inc., Thousand Oaks, California, data on file (2010).
   Google Scholar
• Beck JM, Azari ED. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J.53(1), 71–104 (1998).
   PubMed Web of Science ®Google Scholar
• Bermpohl D, You Z, Lo EH, Kim HH, Whalen MJ. TNF a and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice. J. Cereb. Blood Flow Metab.27(11), 1806–1818 (2007).
   PubMedGoogle Scholar
• Liesz A, Suri-Payer E, Veltkamp C et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat. Med.15(2), 192–199 (2009).
   PubMed Web of Science ®Google Scholar
• Marousi S, Ellul J, Karakantza M. Genetic polymorphisms of type-1 and type-2 inflammatory cytokines in ischaemic stroke. Vasc. Dis. Prev.5(2), 89–103 (2008).
   Google Scholar
• Zaremba J, Losy J. Early TNF-α levels correlate with ischaemic stroke severity. Acta Neurol. Scand.104(5), 288–295 (2001).
   PubMed Web of Science ®Google Scholar
• Zaremba J, Skrobanski P, Losy J. Tumour necrosis factor-α is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct. Biomed. Pharmacother.55(5), 258–263 (2001).
   PubMed Web of Science ®Google Scholar
• Hayashi M, Ueyama T, Nemoto K, Tamaki T, Senba E. Sequential mRNA expression for immediate early genes, cytokines, and neurotrophins in spinal cord injury. J. Neurotrauma17(3), 203–218 (2000).
   PubMed Web of Science ®Google Scholar
• Hermann GE, Rogers RC, Bresnahan JC, Beattie MS. Tumor necrosis factor-α induces cFOS and strongly potentiates glutamate-mediated cell death in the rat spinal cord. Neurobiol. Dis.8(4), 590–599 (2001).
   PubMed Web of Science ®Google Scholar
• Yune TY, Chang MJ, Kim SJ et al. Increased production of tumor necrosis factor-α induces apoptosis after traumatic spinal cord injury in rats. J. Neurotrauma20(2), 207–219 (2003).
   PubMed Web of Science ®Google Scholar
• Kurt G, Ergun E, Cemil B et al. Neuroprotective effects of infliximab in experimental spinal cord injury. Surg. Neurol.71(3), 332–336; discussion 336 (2009).
   PubMedGoogle Scholar
• Peng XM, Zhou ZG, Glorioso JC, Fink DJ, Mata M. Tumor necrosis factor-α contributes to below-level neuropathic pain after spinal cord injury. Ann. Neurol.59(5), 843–851 (2006).
   PubMed Web of Science ®Google Scholar
• Sharma HS, Winkler T, Stalberg E, Gordh T, Alm P, Westman J. Topical application of TNF-α antiserum attenuates spinal cord trauma induced edema formation, microvascular permeability disturbances and cell injury in the rat. Acta Neurochir. Suppl.86, 407–413 (2003).
   PubMedGoogle Scholar
• Genovese T, Mazzon E, Crisafulli C et al. Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J. Pharmacol. Exp. Ther.316(3), 1006–1016 (2006).
   PubMed Web of Science ®Google Scholar
• Genovese T, Mazzon E, Crisafulli C et al. Combination of dexamethasone and etanercept reduces secondary damage in experimental spinal cord trauma. Neuroscience150(1), 168–181 (2007).
   Google Scholar
• Marchand F, Tsantoulas C, Singh D et al. Effects of etanercept and minocycline in a rat model of spinal cord injury. Eur. J. Pain13(7), 673–681 (2009).
   PubMed Web of Science ®Google Scholar
• Dinomais M, Stana L, Egon G, Richard I, Menei P. Significant recovery of motor function in a patient with complete T7 paraplegia receiving etanercept. J. Rehabil. Med.41(4), 286–288 (2009).
   PubMed Web of Science ®Google Scholar
• Chi LY, Yu J, Zhu H, Li XG, Zhu SG, Kindy MS. The dual role of tumor necrosis factor-α in the pathophysiology of spinal cord injury. Neurosci. Lett.438(2), 174–179 (2008).
   Google Scholar
• Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci.9(1), 46–56 (2008).
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood–brain barrier: bottleneck in brain drug development. NeuroRx2(1), 3–14 (2005).
   PubMedGoogle Scholar
• Banks WA. Are the extracellular pathways a conduit for the delivery of therapeutics to the brain? Curr. Pharm. Des.10(12), 1365–1370 (2004).
   PubMed Web of Science ®Google Scholar
• Banks WA, Plotkin SR, Kastin AJ. Permeability of the blood–brain barrier to soluble cytokine receptors. Neuroimmunomodulation2(3), 161–165 (1995).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood101(2), 466–468 (2003).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Abrey L et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol.25(11), 1350–1356 (2007).
   PubMed Web of Science ®Google Scholar
• Boettger MK, Weber K, Grossmann D et al. Spinal TNF-α neutralization reduces peripheral inflammation and hyperalgesia and suppresses autonomic responses in experimental arthritis. Arthritis Rheum. DOI: 10.1002/art.27380 (2010) (Epub ahead of print).
   Google Scholar
• Tobinick E. Spinal delivery of p38: TNF-α inhibitors. PLoS Med.3(11), e511 (2006).
   Google Scholar
• Tobinick EL. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin. Ther.25(8), 2279–2288 (2003).
   PubMed Web of Science ®Google Scholar
• Tobinick EL. A critique of intradiscal administration for treatment of radiculopathy. Anesthesiology108(2), 334; author reply 335 (2008).
   Google Scholar
• Tancredi V, D’Arcangelo G, Grassi F et al. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci. Lett.146(2), 176–178 (1992).
   Web of Science ®Google Scholar
• Netter F. The CIBA Collection of Medical Illustrations. Volume 1: Nervous System; Part I: Anatomy and Physiology. Ciba Pharmaceutical Products, Inc., NJ, USA (1953).
   Google Scholar
• Dahl E, Cohen SP. Perineural injection of etanercept as a treatment for postamputation pain. Clin. J. Pain24(2), 172–175 (2008).
   PubMed Web of Science ®Google Scholar
• Cohen SP, Wenzell D, Hurley RW et al. A double-blind, placebo-controlled, dose–response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology107(1), 99–105 (2007).
   PubMed Web of Science ®Google Scholar
• Malik K. Epidural etanercept for lumbar radiculopathy. Anaesth. Intensive Care35(2), 301–302 (2007).
   Google Scholar
• Serratrice J, de Roux-Serratrice C, Disdier P, Dode C, Weiller PJ. Dramatic etanercept-induced remission of relapsing febrile sciatic neuralgia related to p46l mutation of the tnfrsf1a gene. Clin. Rheumatol.26(9), 1535–1536 (2007).
   Google Scholar
• McAlpine FE, Tansey MG. Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s. J. Inflam. Res.1, 29–39 (2008).
   PubMedGoogle Scholar
• McNaull BB, Todd S, McGuinness B, Passmore AP. Inflammation and anti-inflammatory strategies for Alzheimer’s disease – a mini-review. Gerontology56(1), 3–14 (2009).
   Google Scholar
• Teeling JL, Perry VH. Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience158(3), 1062–1073 (2009)
   PubMed Web of Science ®Google Scholar